Clinical Development of New Antibody-Drug Conjugates in Breast Cancer: To Infinity and Beyond.

BioDrugs · 2021 · PMC7933915 · PMID 33666903

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Furthermore, an exploratory analysis from the ASCENT study specifically in the population with stable brain metastases showed a trend in PFS favoring sacituzumab over TPC (2.8 vs. 1.6 months) [ 50 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.